Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies.

Autor: van Putten EHP; Department of Neurosurgery, Brain Tumor Center, Erasmus University Medical Center, Rotterdam, the Netherlands., Kleijn A; Department of Neurosurgery, Brain Tumor Center, Erasmus University Medical Center, Rotterdam, the Netherlands., van Beusechem VW; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, the Netherlands., Noske D; Department of Neurosurgery, Brain Tumor Center/Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, the Netherlands., Lamers CHJ; Laboratory of Tumor Immunology, Department of Medical Oncology, Erasmus MC-Cancer Institute, Rotterdam, the Netherlands., de Goede AL; Department of Pharmacy, Radboud University Medical Center, Nijmegen, the Netherlands., Idema S; Department of Neurosurgery, Brain Tumor Center/Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, the Netherlands., Hoefnagel D; Department of Neurosurgery, Brain Tumor Center, Erasmus University Medical Center, Rotterdam, the Netherlands., Kloezeman JJ; Department of Neurosurgery, Brain Tumor Center, Erasmus University Medical Center, Rotterdam, the Netherlands., Fueyo J; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lang FF; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas., Teunissen CE; Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, VU University Medical Center, Vrije Universiteit Amsterdam, the Netherlands., Vernhout RM; Clinical Trial Center, Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands., Bakker C; Team Biosafety, Division of Safety & Environment, Support Service, Erasmus University Medical Center, Rotterdam, the Netherlands., Gerritsen W; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Curiel DT; Division of Cancer Biology and Biologic Therapeutics Center, Department of Radiation Oncology, School of Medicine, Washington University in St. Louis, St. Louis, Missouri., Vulto A; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands., Lamfers MLM; Department of Neurosurgery, Brain Tumor Center, Erasmus University Medical Center, Rotterdam, the Netherlands., Dirven CMF; Department of Neurosurgery, Brain Tumor Center, Erasmus University Medical Center, Rotterdam, the Netherlands.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Apr 14; Vol. 28 (8), pp. 1572-1585.

Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer.

Autor: Hurkmans DP; Department of Pulmonology, Erasmus University Medical Center, Rotterdam, The Netherlands d.hurkmans@erasmusmc.nl shvdburg@lumc.nl.; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands., Verdegaal EME; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands., Hogan SA; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland., de Wijn R; PamGene International B.V, HH 's-Hertogenbosch, The Netherlands., Hovestad L; PamGene International B.V, HH 's-Hertogenbosch, The Netherlands., van den Heuvel DMA; PamGene International B.V, HH 's-Hertogenbosch, The Netherlands., Ruijtenbeek R; PamGene International B.V, HH 's-Hertogenbosch, The Netherlands., Welters MJP; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands., van Brakel M; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands., Basak EA; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands., Pinedo HM; PamGene International B.V, HH 's-Hertogenbosch, The Netherlands., Lamers CHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands., van de Werken HJG; Department of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.; Cancer Computational Biology Center, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands., Groten JP; PamGene International B.V, HH 's-Hertogenbosch, The Netherlands., Debets R; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands., Levesque MP; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland., Dummer R; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland., Kapiteijn E; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands., Aerts JGJV; Department of Pulmonology, Erasmus University Medical Center, Rotterdam, The Netherlands., van der Burg SH; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands d.hurkmans@erasmusmc.nl shvdburg@lumc.nl.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2020 Dec; Vol. 8 (2).

Double Umbilical Cord Blood Transplantation in High-Risk Hematological Patients: A Phase II Study Focusing on the Mechanism of Graft Predominance.

Autor: Kalin B; Erasmus University Medical Center, Department of Hematology, Rotterdam, Netherlands., Ter Borg M; Erasmus University Medical Center, Department of Hematology, Rotterdam, Netherlands., Wijers R; Erasmus MC Cancer Institute, Laboratory of Tumor Immunology, Department of Medical Oncology, Rotterdam, Netherlands., Somers JAE; Erasmus University Medical Center, Department of Hematology, Rotterdam, Netherlands.; Sanquin Blood Supply, Department of Transfusion Medicine, Rotterdam, Netherlands., van der Holt B; Erasmus MC Cancer Institute, HOVON Data Center, Department of Hematology, Rotterdam, Netherlands., van Bergen CAM; Leiden University Medical Center, Department of Hematology, Leiden, Netherlands., Petersen EJ; University Medical Center Utrecht, Department of Hematology, Utrecht, Netherlands., Kuball J; University Medical Center Utrecht, Department of Hematology, Utrecht, Netherlands., Meijer E; Amsterdam University Medical Center, VU Medical Center, Department of Hematology, Cancer Center Amsterdam, Amsterdam, Netherlands., Schaap NPM; Radboud University Medical Center, Department of Hematology, Nijmegen., Zeerleder SS; Amsterdam Medical Center, Department of Hematology, Amsterdam, Netherlands., Broers AE; Erasmus University Medical Center, Department of Hematology, Rotterdam, Netherlands., Braakman E; Erasmus University Medical Center, Department of Hematology, Rotterdam, Netherlands., Falkenburg JHF; Leiden University Medical Center, Department of Hematology, Leiden, Netherlands., Lamers CHJ; Erasmus MC Cancer Institute, Laboratory of Tumor Immunology, Department of Medical Oncology, Rotterdam, Netherlands., Cornelissen JJ; Erasmus University Medical Center, Department of Hematology, Rotterdam, Netherlands.

Publikováno v: HemaSphere [Hemasphere] 2019 Aug 09; Vol. 3 (4), pp. e285. Date of Electronic Publication: 2019 Aug 09 (Print Publication: 2019).

Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS.

Autor: de Goeje PL; Department of Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands.; Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, Netherlands., Klaver Y; Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, Netherlands.; Department of Medical Oncology, Laboratory of Tumor Immunology, Erasmus MC, Rotterdam, Netherlands., Kaijen-Lambers MEH; Department of Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands.; Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, Netherlands., Langerak AW; Department of Immunology, Laboratory Medical Immunology, Erasmus MC, Rotterdam, Netherlands., Vroman H; Department of Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands.; Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, Netherlands., Kunert A; Department of Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands.; Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, Netherlands.; Department of Medical Oncology, Laboratory of Tumor Immunology, Erasmus MC, Rotterdam, Netherlands., Lamers CHJ; Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, Netherlands.; Department of Medical Oncology, Laboratory of Tumor Immunology, Erasmus MC, Rotterdam, Netherlands., Aerts JGJV; Department of Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands.; Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, Netherlands., Debets R; Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, Netherlands.; Department of Medical Oncology, Laboratory of Tumor Immunology, Erasmus MC, Rotterdam, Netherlands., Hendriks RW; Department of Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands.

Publikováno v: Frontiers in immunology [Front Immunol] 2018 Sep 07; Vol. 9, pp. 2034. Date of Electronic Publication: 2018 Sep 07 (Print Publication: 2018).

Graft predominance after double umbilical cord blood transplantation: a review.

Autor: Cornelissen JJ; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Kalin B; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Lamers CHJ; Laboratory of Tumor Immunology, Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Publikováno v: Stem cell investigation [Stem Cell Investig] 2017 May 26; Vol. 4, pp. 47. Date of Electronic Publication: 2017 May 26 (Print Publication: 2017).